

**P&T Motion History**  
**Long-Acting Insulins for Type 1 and Type 2 Diabetes**

| Drugs Reviewed  | Motion   | Date Reviewed     | Scan Accepted as Adequate | Reiteration of Prior Motion | Decision         |
|---|--|-------------------|---------------------------|-----------------------------|------------------|
| insulin detemir<br><b>insulin degludec*</b><br><b>insulin degludec/</b><br><b>insulin aspart*</b><br>insulin glargine | After considering the evidence of safety, efficacy and special populations for the treatment of type 1 and type 2 diabetes, I move that insulin detemir and insulin glargine are safe and efficacious for the treatment of their approved indications. Long-acting insulins can be subject to therapeutic interchange in the Washington preferred drug list. | December 21, 2016 | Yes<br>Harvey Sanderson   | Yes<br>Klingel Bowman       | Passed unanimous |

\*Not eligible for inclusion on the PDL  
 Bold =new this review